OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
ECCO '19 Copenhagen
2019
OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis
ECCO '19 Copenhagen
2019
OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture
ECCO '19 Copenhagen
2019
OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptake
ECCO '19 Copenhagen
2019
OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI Phase 3 induction study
ECCO '19 Copenhagen
2019
OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study
ECCO '19 Copenhagen
2019
OP15: Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?
ECCO '19 Copenhagen
2019
OP16: A randomised, multi-centre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild-to-moderate ulcerative colitis: efficacy results
ECCO '19 Copenhagen
2019
OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
ECCO '19 Copenhagen
2019
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
ECCO '19 Copenhagen
2019
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
ECCO '19 Copenhagen
2019
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
ECCO '19 Copenhagen
2019
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
ECCO '19 Copenhagen
2019
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
ECCO '19 Copenhagen
2019
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease
ECCO '19 Copenhagen
2019
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
ECCO '19 Copenhagen
2019